此外，诺瓦瓦克斯医药以2亿美元的价格将其捷克设施出售给丹麦制药公司诺和诺德公司，这是精简运营并专注于疫苗开发的战略举措。在其第三季度财报中，诺瓦瓦克斯医药披露收入降至8500万美元，低于去年同期的1.87亿美元。

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Myocardial Infarction.

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

In the most recent trading session, Novo Nordisk (NVO) closed at $85.73, indicating a -1.88% shift from the previous trading day.

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a ...